FDG PET Imaging Study of Brain Metabolic Change in Chronic Cancer Pain Patient: a Retrospective Analysis
Overview
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 119
- Locations
- 1
- Primary Endpoint
- Find the location of brain metabolic changes, pain scale
Overview
Brief Summary
Cancer pain deteriorated in quality of life and related with numerous psychosocial problems. Over the one third of cancer patient suffered from moderate to severe cancer pain, even under adequate pain management.
The 18F-fluoro-2-deoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) images can provide quantitative results in clinical oncology. As a functional neuroimaging, the PET evidently provided anatomical activated regions, size, and spatial extent information. In this retrospective study, we use FDG-PET to investigate changes concerning the glucose metabolism in the brain with or without cancer pain.
Study Design
- Study Type
- Observational
- Observational Model
- Other
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 20 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •cancer patient
Exclusion Criteria
- •no brain metastasis
Outcomes
Primary Outcomes
Find the location of brain metabolic changes, pain scale
Time Frame: 12 months
This retrospective analysis only compare image and clinical record including pain scale
Secondary Outcomes
No secondary outcomes reported